FTC approves Novartis divestiture
The Federal Trade Commission gave final approval to Novartis’ divesting of assets related to its BRAF- and MEK-inhibitor drugs to satisfy the agency’s concerns that the drugmaker’s $16 billion acquisition of...To view the full article, register now.
Already a subscriber? Click here to view full article